Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ta

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among […]

Related Keywords

Canada , Blackrock , Nova Scotia , Piper Sandler , Gareng Bohlin , Royal Bank , Karyopharm Therapeutics Inc , Morgan Stanley , Karyopharm Therapeutics Company Profile , Blackrock Inc , Securities Exchange Commission , Marshall Wace , Selective Inhibitor Of Nuclear Export , Nasdaq , Karyopharm Therapeutics , Get Free Report , Director Garen , Exchange Commission , Street Corp , Point Capital Management , Get Free , Therapeutics Inc , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti , Kpti , Medical , Ratings , Consensus ,